Ajai Pal

Ajai Pal is a seasoned professional in the field of toxicology, currently serving as Senior Director at Scholar Rock since 2020. Prior experience includes roles at Genmab as Associate Director of Non-Clinical Safety, where responsibilities involved leading IND-enabling safety evaluations for bispecific T-cell engager antibodies in immuno-oncology. Ajai Pal also held the position of Associate Director of Toxicology at Glenmark Pharmaceuticals, leading nonclinical safety assessments for novel biologics. Previous work experience includes senior positions at Spark Therapeutics, where oversight of AAV-based gene therapy safety assessments took place, and at Celgene, where Ajai Pal contributed to five accepted INDs through comprehensive nonclinical safety evaluations. Early career experiences involved significant roles in pre-clinical drug development at NeoPharm and research instruction at the University of Pittsburgh School of Medicine. Academic qualifications include a MiniMBA in Bio Pharma Innovation from Rutgers University, a Post Doctorate in Pharmacology from the University of Pittsburgh, and a PhD in Biology from the Central Drug Research Institute in India.